keyword
MENU ▼
Read by QxMD icon Read
search

rituximab hepatitis b reactivation

keyword
https://www.readbyqxmd.com/read/28339910/rituximab-and-hepatitis-b-reactivation-in-hbsag-negative-anti-hbc-positive-kidney-transplant-recipients
#1
Juhan Lee, Jun Yong Park, Kyu Ha Huh, Beom Seok Kim, Myoung Soo Kim, Soon Il Kim, Hoon Sang Ahn, Yu Seun Kim
Background.: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy. Although rituximab is increasingly used for desensitization of ABO-incompatible or positive crossmatch kidney transplantation, the risk of HBV reactivation in hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (anti-HBc)-positive kidney transplant patients receiving rituximab desensitization remains undetermined. Methods.: We analysed 172 resolved HBV patients who underwent living donor kidney transplantation between 2008 and 2014...
February 23, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28140702/antiviral-therapies-for-managing-viral-hepatitis-in-lymphoma-patients
#2
REVIEW
Michele Merli, Sara Rattotti, Manuel Gotti, Luca Arcaini
In patients with lymphoma the detection of positive hepatitis B or C viruses (HBV and HCV) serology involves crucial therapeutic consequences. In HBV-infected patients the serological profile of active (HBsAg-positive) or resolved (HBsAg-negative/anti-HBcAb-positive) infection is associated to differential risk of viral reactivation during rituximab-based therapy and require appropriate strategies of monitoring and of antiviral prophylaxis. In HCV-associated NHL patients consolidated data demonstrated that interferon (IFN)-based antiviral therapy (AT) is able to induce lymphoma regression strictly related to viral eradication, while preliminary data of the new direct-acting antivirals (DAAs) are very promising...
March 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28128861/role-of-surface-antibody-in-hepatitis-b-reactivation-in-patients-with-resolved-infection-and-hematologic-malignancy-a-meta-analysis
#3
Sonali Paul, Aaron Dickstein, Akriti Saxena, Norma Terrin, Kathleen Viveiros, Ethan M Balk, John B Wong
Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation. Because of conflicting studies about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against reactivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hematological malignancies, we conducted a meta-analysis to determine if anti-HBs reduces HBV reactivation risk. We sought English language studies through March 1, 2016 in Medline and other sources that examined reactivation in patients with resolved HBV infection receiving chemotherapy for hematologic malignancies...
January 27, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28011918/hepatitis-b-virus-reactivation-in-rheumatoid-arthritis-patients-undergoing-biologics-treatment
#4
Ming-Han Chen, Ming-Huang Chen, Chun-Yu Liu, Chang-Youh Tsai, De-Feng Huang, Hsiao-Yi Lin, Mei-Hsuan Lee, Yi-Hsiang Huang
BACKGROUND: Immunosuppressants can induce hepatitis B virus(HBV) reactivation, however, informative data regarding the risk of different immunosuppressive regimens including biologics on HBV reactivation(HBVr) among patients with rheumatoid arthritis(RA) is unsettled. METHODS: Among 2334 RA patients who had available HBsAg data, 123 patients positive for hepatitis B surface antigen(HBsAg) without receiving anti-HBV prophylaxis were enrolled. These patients undergoing varied mono- or combination immunosuppressive therapy, including 36 receiving biological disease-modifying antirheumatic drugs(bDMARDs)...
December 23, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27747531/rituximab-for-rheumatoid-arthritis
#5
REVIEW
Marc D Cohen, Edward Keystone
Rituximab is a chimeric monoclonal antibody directed at the CD20 molecule on the surfaces of some but not all B cells. It depletes almost all peripheral B cells, but other niches of B cells are variably depleted, including synovium. Its mechanism of action in rheumatoid arthritis (RA) is only partially understood. Rituximab was efficacious in clinical trials of patients with RA, including those who are methotrexate naïve, those with an incomplete response to methotrexate, and those with an incomplete response to tumor necrosis factor inhibitors...
December 2015: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27743784/-hepatitis-b-virus-reactivation-after-cessation-of-prophylaxis-with-entecavir-in-a-patient-with-burkitt-type-acute-lymphoblastic-leukaemia-treated-with-rituximab
#6
Alba Juan Juan, Noemi Caballero de García, Helena Masnou Ridaura, Marga Sala Llinas, M Rosa Morillas, Ramon Planas Vila
No abstract text is available yet for this article.
October 12, 2016: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/27708965/viral-hepatitis-screening-guideline-before-biological-drug-use-in-rheumatic-patients
#7
REVIEW
Ömer Karadağ, Timuçin Kaşifoğlu, Birol Özer, Sabahattin Kaymakoğlu, Yeşim Kuş, Murat İnanç, Gökhan Keser, Sedat Kiraz
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary...
March 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27696389/improvements-in-hepatitis-b-virus-screening-before-rituximab-therapy-a-community-based-safety-net-hospital-experience
#8
Kevin Junus, Maria Aguilar, Priya Patel, David Irwin, Stephen Yee, Benny Liu, Taft Bhuket, Robert J Wong
BACKGROUND: Individuals with chronic hepatitis B virus infection (HBV) or previously resolved HBV are at increased risk of HBV exacerbation or reactivation when they receive treatment with anti-CD20 monoclonal antibodies (against B-lymphocyte antigen cluster of differentiation 20 [CD20], an activated-glycosylated phosphoprotein) like rituximab (RTX). The objective of the current study was to evaluate the rates of appropriate HBV screening before patients started receiving RTX, at the initiation of HBV treatment, and during HBV flares among an underserved safety-net population...
October 3, 2016: Cancer
https://www.readbyqxmd.com/read/27669175/efficacy-of-prophylactic-antiviral-therapy-and-outcomes-in-hbsag-negative-anti-hbc-positive-patients-receiving-chemotherapy-a-real-life-experience
#9
Nikolaos Papadopoulos, Melanie Deutsch, Spilios Manolakopoulos, Chrysoula Bitsi, Helias Michalakeas, Helias Poulakidas, Eftychia Tsironi, Stavroula Giannouli, George V Papatheodoridis, John Koskinas, Dimitrios Pectasides
OBJECTIVE: The aim of this study is to evaluate the outcomes of hepatitis B surface antigen (HBsAg)-negative, anti-HBc-positive patients who received immunosuppressive therapies. PATIENTS AND METHODS: We retrospectively evaluated the medical records of HBsAg-negative, anti-HBc-positive patients with hematological diseases or solid tumors who underwent immunosuppressive therapies and were referred because of positive baseline hepatitis B virus (HBV) serology or HBV reactivation...
January 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27665181/delayed-hbv-reactivation-in-rituximab-containing-chemotherapy-how-long-should-we-continue-anti-virus-prophylaxis-or-monitoring-hbv-dna
#10
Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura
Reactivation of hepatitis B virus (HBV) infection is a well-recognized and potentially fatal complication in patients treated with chemotherapy for lymphoid malignancies. Although several guidelines recommend antiviral prophylaxis and/or monitoring for HBV-DNA, there is no consensus over what time period these should occur. Clinically, we have encountered delayed reactivation of HBV infections and have reported 12 cases of reactivation in patients. Among them, five patients developed HBV reactivation more than a year after they completed their chemotherapy...
November 2016: Leukemia Research
https://www.readbyqxmd.com/read/27644733/association-of-hepatitis-b-core-related-antigen-with-hepatitis-b-virus-reactivation-in-occult-viral-carriers-undergoing-high-risk-immunosuppressive-therapy
#11
Wai-Kay Seto, DannyKa-Ho Wong, ThomasSau-Yan Chan, Yu-Yan Hwang, James Fung, Kevin Sze-Hang Liu, Harinder Gill, Yuk-Fai Lam, Ka-Shing Cheung, Albert K W Lie, Ching-Lung Lai, Yok-Lam Kwong, Man-Fung Yuen
OBJECTIVES: Hepatitis B core-related antigen (HBcrAg) is a novel serum marker that correlates with intrahepatic hepatitis B virus (HBV) activity. Its association with HBV reactivation in hepatitis B surface antigen (HBsAg)-negative antibody to hepatitis B core antigen (anti-HBc)-positive patients undergoing high-risk immunosuppressive therapy is undefined. METHODS: HBcrAg was measured in HBsAg-negative, anti-HBc-positive Asian patients with undetectable HBV DNA, who participated in two prospective studies investigating HBV reactivation during rituximab-containing chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT)...
December 2016: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27605883/prevention-and-management-of-hepatitis-b-virus-reactivation-in-patients-with-hematological-malignancies-treated-with-anticancer-therapy
#12
REVIEW
Man Fai Law, Rita Ho, Carmen K M Cheung, Lydia H P Tam, Karen Ma, Kent C Y So, Bonaventure Ip, Jacqueline So, Jennifer Lai, Joyce Ng, Tommy H C Tam
Hepatitis due to hepatitis B virus (HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti-HBc)...
July 28, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27590841/high-rate-of-hepatitis-b-viral-breakthrough-in-elderly-non-hodgkin-lymphomas-patients-treated-with-rituximab-based-chemotherapy
#13
Roberto Castelli, Laurenzia Ferraris, Giuseppe Pantaleo, Giorgio Lambertenghi Deliliers, Marco Cicardi
BACKGROUND: Rituximab-containing chemotherapies are offered to elderlies for treatment of non-Hodgkin lymphomas (NHL). From 0.7 to 27% of patients with "resolved" HBV infection develop HBV reactivation and related hepatitis during Rituximab-containing chemotherapies. Currently, several antiviral drugs are available for the prophylaxis of patients at risk for HBV reactivation, which include lamivudine, tenofovir, entecavir, and adefovir. Viral breakthrough may occur during therapy, which is defined as an abrupt increase in serum HBV DNA levels after a period of persistent suppression...
November 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/27569942/safety-of-monitoring-viral-and-liver-function-markers-in-patients-with-prior-resolved-hepatitis-b-infection-after-kidney-transplantation
#14
H Maekawa, M Yazawa, K Koitabashi, N Imai, H Kawarazaki, R Nakazawa, H Sasaki, T Chikaraishi, Y Shibagaki
BACKGROUND: Hepatitis B virus (HBV) infection is a risk factor of mortality in kidney transplant recipients. However, information on the risk of HBV reactivation in kidney recipients with prior resolved HBV infection is limited. This study aimed to evaluate the safety of simply monitoring viral and liver markers in living donor kidney transplantation (LDKT) recipients with prior resolved HBV infection. METHODS: We retrospectively examined the clinical records of LDKT recipients...
July 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27468211/hepatitis-c-virus-associated-b-cell-non-hodgkin-s-lymphoma
#15
REVIEW
Romeo-Gabriel Mihăilă
The hepatitis C virus (HCV) infected patients are prone to develop bone marrow or various tissue infiltrates with monoclonal B cells, monoclonal B lymphocytosis or different types of B cell non-Hodgkin's lymphoma (BCNHL), of which the most common are splenic marginal zone BCNHL, diffuse large BCNHL and follicular lymphoma. The association between chronic HCV infection and non Hodgkin's lymphoma has been observed especially in areas with high prevalence of this viral infection. Outside the limitations of some studies that have been conducted, there are also geographic, environmental, and genetic factors that contribute to the epidemiological differences...
July 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27388147/improving-testing-for-hepatitis-b-before-treatment-with-rituximab
#16
Jessica K Dyson, Laura Jopson, Sarah Ng, Matthew Lowery, Jayne Harwood, Sheila Waugh, Manoj Valappil, Stuart McPherson
AIMS/OBJECTIVES/BACKGROUND: Individuals with current or previous infection with the hepatitis B virus (HBV) can experience viral reactivation when treated with immunosuppression. Rituximab, an anti-CD20 antibody used to treat many diseases, has potent immunosuppressant effects with a high risk of causing HBV reactivation. Reactivation can range from elevated liver enzymes to acute severe hepatitis with liver failure and a significant mortality risk. HBV screening and appropriate use of prophylactic antiviral therapy can prevent reactivation...
October 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27383049/safety-profile-of-repeated-rituximab-cycles-in-unselected-rheumatoid-arthritis-patients-a-long-term-prospective-real-life-study
#17
MULTICENTER STUDY
Dimitrios Vassilopoulos, Evie M Delicha, Loukas Settas, Alexandros Andrianakos, Spyros Aslanidis, Panagiota Boura, Marios Katsounaros, Panagiotis Athanassiou, Konstantinos Tempos, Grigorios Skarantavos, Christodoulos Antoniadis, Sotirios Papazoglou, Lazaros Sakkas, Vassiliki Galanopoulou, Fotini Skopouli, Kyriaki Boki, Dimitrios Daoussis, Eleni Vritzali, Petros P Sfikakis
OBJECTIVES: To evaluate the long-term safety of rituximab (RTX) in rheumatoid arthritis (RA) patients in daily clinical practice. METHODS: This was a multicentre (17 Greek Rheumatology sites), prospective, long-term, pharmacovigilance study of patients with moderate to severe RA and an inadequate response or intolerance to ≥1 anti-tumour necrosis factor (TNF) agents. Adverse events (AEs) were recorded and collected prospectively every 2-6 months. RESULTS: 234 patients (mean age: 59±12...
September 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27350944/hepatitis-b-reactivation-with-novel-agents-in-non-hodgkin-s-lymphoma-and-prevention-strategies
#18
REVIEW
Oluwatobi O Ozoya, Lubomir Sokol, Samir Dalia
Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world despite available prophylactic vaccines. Non-Hodgkin's lymphoma is the most common hematological malignancy, and certain patients undergoing therapy are at increased risk of HBV reactivation. Rituximab, a monoclonal antibody, is well studied in HBV reactivation, but newer agents have been implicated as well. Here, we review novel agents suspected in HBV reactivation and effective strategies to prevent HBV reactivation. Fifteen years of literature were reviewed in order to better understand the reactivation rates of hepatitis B in patients with non-Hodgkin's lymphoma...
June 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/27311286/-latest-treatment-of-viral-hepatitis-overcoming-hepatitis-c-and-reactivation-of-hepatitis-b
#19
REVIEW
Yasuhito Tanaka
Hepatitis B virus (HBV) and hepatitis C virus (HCV), discovered as causative viruses of post-transfusion hepatitis, become persistent infections, leading to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). For HCV, recent IFN-free direct-acting antiviral (DAA) therapies have increased sustained virological response (SVR) rates and reduced adverse events. IFN-based therapies, still the standard of care in Asian countries, are influenced by IL28B genetic variants and the liver fibrosis stage, but the DAA combinations obscure the influence of these factors...
February 2016: Rinsho Byori. the Japanese Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27299166/-reactivation-of-resolved-hepatitis-b-in-hbsag-negative-patients-receiving-rituximab-a-preemptive-strategy
#20
COMMENT
O Epaulard
No abstract text is available yet for this article.
February 2016: Médecine et Maladies Infectieuses
keyword
keyword
110035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"